BioMark Diagnostics (BUX) AI Stock Analysis

• Market Cap: C$37.83M
• Dividend Yield: N/A
• Average Volume (3M): 25.71K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.40
• Revenue Growth: -4.26%
• EPS Growth: 4.32%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 53
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 105,090,210
• 10 Day Avg. Volume: 10,002
• 30 Day Avg. Volume: 25,707
• PEG Ratio: 0.71
• Price to Book (P/B): -41.95
• Price to Sales (P/S): 156.67
• P/FCF Ratio: -25.91
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$0.50
• Price Target Upside: 38.89% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 48 Neutral
• Price Target: C$0.50 ▲(38.89% Upside)

The overall stock score is primarily impacted by significant financial challenges, including declining revenues and profitability issues. While technical indicators show some positive price trends, the negative P/E ratio and lack of dividend yield weigh heavily on the valuation. Improvements in leverage and cash flow growth provide some positive aspects, but the overall outlook remains cautious.

Positive Factors

Cash Flow Improvement

The improvement in free cash flow growth indicates better cash generation capabilities, which can support operational needs and future investments.

Leverage Management

Improved leverage management reflects better financial discipline, reducing financial risk and enhancing stability in the long term.

High Gross Profit Margins

High gross profit margins suggest strong pricing power and cost management, providing a buffer against operational inefficiencies.

Negative Factors

Declining Revenue Trend

The significant decline in revenue indicates challenges in market demand or competitive positioning, impacting long-term growth prospects.

Profitability Issues

Persistent profitability challenges highlight operational inefficiencies, which can undermine financial sustainability and investor confidence.

Negative Return on Equity

Negative return on equity suggests the company is not effectively utilizing shareholder investments to generate profits, affecting long-term value creation.

BioMark Diagnostics Business Overview & Revenue Model

Company Description

BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.

How the Company Makes Money

BioMark Diagnostics generates revenue through the sale of its diagnostic testing services and products, which are aimed at healthcare providers, hospitals, and laboratories. The company charges fees for each test conducted, with pricing structures that may vary based on test complexity and volume. Additionally, BioMark may engage in partnerships with pharmaceutical companies and research institutions for collaborative projects, which can bring in revenue through licensing agreements and research funding. The company also potentially benefits from grants and investments aimed at advancing its technology and expanding its market reach.

BioMark Diagnostics Financial Statement Overview

Summary

BioMark Diagnostics faces significant financial challenges, with declining revenues and persistent profitability issues. Improvements in leverage and cash flow growth are noted, but negative returns on equity and cash flow deficits remain significant concerns.

Income Statement

BioMark Diagnostics has shown a declining revenue trend with a negative revenue growth rate of -52.4% in the latest year. The company consistently reports negative net profit margins, with the latest at -12.5%, indicating ongoing profitability challenges. While gross profit margins remain high at 100%, this is overshadowed by significant EBIT and EBITDA losses, reflecting operational inefficiencies.

Balance Sheet

The company has improved its debt-to-equity ratio to 0.26, indicating better leverage management compared to previous years. However, the return on equity remains negative at -110.7%, suggesting the company is not generating sufficient returns on shareholder investments. The equity ratio is also low, highlighting potential financial instability.

Cash Flow

BioMark Diagnostics has shown a positive free cash flow growth rate of 27.6%, indicating some improvement in cash generation. However, both operating and free cash flows remain negative, and the operating cash flow to net income ratio is below 1, suggesting cash flow challenges relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	154.90K	154.22K	163.22K	153.49K	43.93K	0.00
Gross Profit	154.90K	154.22K	163.22K	-232.70K	43.93K	-13.69K
EBITDA	-1.22M	-1.46M	-919.05K	-1.35M	-1.22M	-1.08M
Net Income	-1.72M	-1.93M	-1.43M	-1.84M	-1.45M	-1.09M
Balance Sheet
Total Assets	2.66M	3.13M	1.09M	732.29K	1.47M	952.94K
Cash, Cash Equivalents and Short-Term Investments	2.09M	2.48M	156.75K	72.04K	382.71K	877.68K
Total Debt	359.19K	454.16K	805.93K	823.87K	1.05M	119.32K
Total Liabilities	1.33M	1.39M	1.70M	1.88M	2.11M	1.03M
Stockholders Equity	1.33M	1.74M	-609.61K	-1.15M	-635.69K	-79.09K
Cash Flow
Free Cash Flow	-1.06M	-1.10M	-986.91K	-919.72K	-1.26M	-455.55K
Operating Cash Flow	-1.06M	-1.09M	-982.52K	-914.42K	-1.20M	-455.55K
Investing Cash Flow	-1.89M	-3.53K	-4.39K	-5.30K	-59.20K	-3.20K
Financing Cash Flow	3.01M	3.42M	1.07M	609.05K	768.16K	724.63K

BioMark Diagnostics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.36
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BUX, the sentiment is Positive. The current price of 0.36 is above the 20-day moving average (MA) of 0.35, above the 50-day MA of 0.35, and above the 200-day MA of 0.27, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 53.41 is Neutral, neither overbought nor oversold. The STOCH value of 74.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BUX.

BioMark Diagnostics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.90B	-0.36	-43.38%	2.23%	22.34%	-2.15%
BUX	48 Neutral	C$37.83M	―	-504.79%	―	-4.26%	4.32%
ADK	46 Neutral	C$26.48M	―	366.78%	―	-47.10%	-19.32%
TELO	28 Underperform	C$7.50M	―	-303.19%	―	―	23.32%
SZLS.H	―	C$4.94M	―		―	―	―
SONA	40 Underperform	C$65.16M	―	-390.46%	―	―	14.29%

BioMark Diagnostics Corporate Events

BioMark Diagnostics Expands into North Africa with Strategic Partnership

BioMark Diagnostics has announced a strategic partnership with SAMA CONSULTING SARL to introduce its liquid biopsy platform for lung cancer detection in Tunisia and potentially expand across North Africa. This collaboration aims to address the high mortality rate from lung cancer in the region by using BioMark’s advanced technology, starting with a proof-of-concept trial in October 2025. The partnership signifies BioMark’s strategic entry into the North African market, leveraging SAMA’s local expertise to facilitate rapid implementation and regulatory compliance, with potential expansion to other countries in the region.

BioMark Diagnostics Expands Laboratory Services to Boost Lung Cancer Assay Commercialization

BioMark Diagnostics Inc. has announced the expansion of its specialty laboratory services in Quebec, which includes the acquisition of advanced equipment that doubles its testing capacity. This strategic move is set to accelerate the commercialization of its metabolomic-based lung cancer diagnostic assay, addressing the increasing global demand for non-invasive liquid biopsy diagnostics. The expansion positions BioMark as a central hub for innovation and high-throughput diagnostics, facilitating international partnerships and enhancing research capabilities. This development supports BioMark’s vision of scalable growth, enabling broader deployment strategies through clinical partnerships and expanding its contract research programs, ultimately enhancing long-term shareholder value.

BioMark Diagnostics Announces 2025 Achievements and Strategic Milestones for 2025-2026

BioMark Diagnostics Inc. announced its fiscal year 2025 achievements and strategic milestones for 2025-2026, showcasing resilience in a challenging funding environment for biotechnology firms. The company secured CAD $4.26 million through a private placement, maintained investor confidence, and achieved significant progress across its strategic pillars, including financial strength, operational advancements, lab certification, and strategic collaborations. Key milestones for the upcoming year include expanding laboratory capacity, completing a pivotal lung cancer clinical trial, and launching commercial operations for its lung cancer assay in Quebec, with plans to secure CLIA certification for U.S. market entry by early 2026.